Malecare, Author at malecare.org

From ASCO 2013 – Updated Analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) from the phase III randomized trial (ALSYMPCA).

Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the phase 3, double-blind, randomized, multinational ALSYMPCA study, Ra-223 significantly improved overall survival (OS) in men with castrate resistant advanced prostate [...]

By Malecare|2017-10-19T10:50:08-04:00March 4th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

FROM THE 2013 ASCO GU CONFERENCE –CHEMOTHERAPY AND THE USE ANTICOAGULANTS INCREASE PROSTATE CANCER SURVIVAL RATES

Another interesting research abstract presented at the Genitourinary Cancers Symposium in Orlando Florida this month found that men with prostate cancer who were on chemotherapy who had also received anticoagulant (blood-thinners) medications experienced improved overall survival rates compared to men who did not take anticoagulants drugs. This retrospective study involved the reviewed of the medical [...]

By Malecare|2013-03-03T14:47:03-05:00March 3rd, 2013|Advanced Prostate Cancer, ASCO, Chemo Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC|1 Comment

More From the 2013 ASCO GU Conference – An Updated Analysis of the Phase III Randomized Trial (ALSYMPCA) of Radium-223 dichloride (Ra-223)

Ra-223 is an investigational alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range alpha-particles. The recently completed phase 3, double-blind, randomized, multinational ALSYMPCA study showed that Ra-223 significantly improved over all survival (OS) in CRPC men with bone mets by a median increase of 3.6 months compared with placebo (median OS: 14.9 vs 11.3 mo; P [...]

By Malecare|2017-10-19T10:50:08-04:00February 28th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized|0 Comments

From the 2013 Genitourinary Cancers Symposium – An Update of the Abiraterone Acetate (Zytiga) with Prednisone Clinical Trial

At the recent 2013 2013 Genitourinary Cancers Symposium there was an abstract presented that updated data from the COU-AA-302 clinical trial of Abiraterone Acetate (Zytiga) with prednisone. The updated data confirms that Zytiga with prednisone improves overall survival (OS) in men with metastatic castrate resistant prostate cancer (mCRPC) post-docetaxel therapy (chemotherapy)(Lancet Oncol 2012;13:983-92). The trial [...]

By Malecare|2017-10-19T10:50:08-04:00February 25th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Zytiga|0 Comments

Sequencing Xtandi – Possibly the ADT of the Future? An Interview with Dr. Bertrand Tombal

There was a recent interview in the Pharma Strategy Blog with Dr. Bertrand Tombal , an academic urologist in Belgium. Dr. Tomal discussed several of the new advances in the treatment od advanced prostate cancer with an emphasis on the potential future of Enzalutamide (Xtandi). Like bicalutamide (Casodex), Xtandi works by blocking (inhibiting) testosterone from [...]

By Malecare|2020-02-04T10:31:31-05:00February 20th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Enzalutamide (MDV-3100), On The Horizon, Uncategorized, Understanding APC, Xtandi|1 Comment

From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

By Malecare|2013-02-17T10:43:04-05:00February 17th, 2013|adjuvant therapy, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized|0 Comments

Two More Provenge Related Abstracts from the 2013 ASCO GU Symposium

More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]

By Malecare|2017-10-19T10:50:08-04:00February 15th, 2013|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, inflammation, Pain, Provenge, Research, Uncategorized, Understanding APC|0 Comments

From the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium – News of Provenge

Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]

By Malecare|2020-02-04T08:56:36-05:00February 14th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Combination Therapy, Drugs & Treatments, Hormone Therapy, Research, Uncategorized|0 Comments

Great News for the Advanced Prostate Cancer Community – The FDA Grants a Priority Review for Radium-223 Dichloride (Alpharadin)

Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223). The application is under review for the treatment of [...]

By Malecare|2020-02-04T08:22:15-05:00February 13th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, FDA, General Information, Uncategorized|0 Comments

Knowing Good from Bad Information Published on the Internet

We all use the Internet to learn about our prostate cancer, your reading this post confirms this statement. The Internet can be a useful tool for finding information and connecting with other patients and caregivers. However, it can also be a nightmare of unreliable misinformation. Understanding what is credible, accurate and reliable information about prostate [...]

By Malecare|2021-02-17T11:03:16-05:00February 12th, 2013|Advanced Prostate Cancer, General Information, How We Live, Uncategorized, Understanding APC|0 Comments

Malecare

About Malecare